Methods for modifying progression of osteoarthritis
AssigneeAllergan, Inc.
InventorsGuang-Liang Jiang, Catherine Turkel
Life of this patent
Estimating the term…
Abstract
Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein.
Claims30
A method for treating osteoarthritis in a patient in need thereof, the method comprising locally administering a therapeutically effective amount of a clostridial derivative to an osteoarthritis-affected site of the patient, thereby treating osteoarthritis in the patient;
- wherein the administering reduces the levels of at least one cartilage-degrading agent, increasing the levels of at least one cartilage-forming component, or both.
The method of claim 7, wherein the botulinum toxin is type A.
The method of claim 8, wherein the therapeutically effective amount is from about 2 units to about 800 units.
A method for delaying progression of osteoarthritis or repairing cartilage defect in a patient in need thereof, the method comprising modifying the levels of at least one cartilage-forming component, one cartilage-degrading agent, or both, by locally administering a therapeutically effective amount of a clostridial derivative to an osteoarthritis-affected site of the patient, thereby delaying progression of osteoarthritis or repairing cartilage defect in the patient.
A method for reversing cartilage breakdown in a patient suffering from osteoarthritis, the method comprising modifying the levels and/or activities of at least one agent associated with osteoarthritis-mediated cartilage breakdown, by locally administering a therapeutically effective amount of a clostridial derivative to an osteoarthritis-affected site of the patient, thereby reversing cartilage breakdown in the patient.
The method of claim 26, wherein the at least one agent associated with osteoarthritis-mediated cartilage degradation comprises a cartilage-degrading agent, a cartilage-forming component, or mixtures thereof.
The method of claim 26, wherein the osteoarthritis-affected site is selected from the group consisting of a knee joint, a hip joint, a hand joint, a shoulder joint, an ankle joint, a foot joint, an elbow joint, a wrist joint, a sacroiliac joint, a spine joint, and combinations thereof.
A method for modifying the levels and/or activities of at least one agent associated with osteoarthritis-mediated cartilage degradation, the method comprising locally administering a therapeutically effective amount of a botulinum toxin type A to an osteoarthritis-affected site of the patient, thereby mitigating the osteoarthritis-mediated cartilage degradation;
- wherein the administering is by intra-articular injection and wherein the therapeutically effective amount is greater than 100 units.
Dependencies are inferred from the claim text.